Completed strategic pivot from R&D focus to commercial focusRebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relationsAdvanced multiple recombinant protein programs toward commercializationAchieved key development and commercial milestones across life sciences and nutrition marketsFirst purchase order received in cell culture media and molecular biology reagent segmentsSecured ERS Genomics CRISPR license to optimize production and produc ...

Core Insights - Dyadic International, Inc. has achieved significant milestone payments in collaborations with Proliant Health & Biologicals and Inzymes ApS, indicating progress in its business transformation and commercial initiatives [1][2] Group 1: Company Developments - Dyadic is transitioning to a commercially focused, revenue-driven company, with substantial progress noted in Q3 2025 across its portfolio [2] - The company is committed to capitalizing on near-term commercialization opportunities, supported by a stronger balance sheet and an expanding pipeline of products [2] Group 2: Life Sciences - Dyadic reached a $500,000 milestone in its partnership with Proliant for Recombinant Human Albumin, with commercialization expected to advance in late 2025 to early 2026 [7] - The company is expanding sampling efforts for Recombinant Transferrin in research, diagnostics, and cultured meat markets, with initial production underway [7] - Dyadic's Recombinant DNase I has met performance benchmarks, validating its utility in molecular biology and diagnostics, with production at research grade ongoing [7] Group 3: Food & Nutrition - A term sheet has been signed for the development of non-animal human alpha-lactalbumin for the infant nutrition market, with initial sampling in progress [7] - Dyadic received a $250,000 milestone payment from Inzymes for non-animal dairy enzymes, with the first enzyme's scale-up on track for a late 2025 launch [7]